Skip Nav Destination
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition
Issue Archive
Table of Contents
INSIDE BLOOD
BLOOD WORK
REVIEW ARTICLES
CLINICAL TRIALS AND OBSERVATIONS
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study
Clinical Trials & Observations
Huei-Ting Tsai,Neil E. Caporaso,Robert A. Kyle,Jerry A. Katzmann,Angela Dispenzieri,Richard B. Hayes,Gerald E. Marti,Maher Albitar,Paolo Ghia,S. Vincent Rajkumar,Ola Landgren
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Clinical Trials & Observations
Gianantonio Rosti,Francesca Palandri,Fausto Castagnetti,Massimo Breccia,Luciano Levato,Gabriele Gugliotta,Adele Capucci,Michele Cedrone,Carmen Fava,Tamara Intermesoli,Giovanna Rege Cambrin,Fabio Stagno,Mario Tiribelli,Marilina Amabile,Simona Luatti,Angela Poerio,Simona Soverini,Nicoletta Testoni,Giovanni Martinelli,Giuliana Alimena,Fabrizio Pane,Giuseppe Saglio,Michele Baccarani,for the GIMEMA CML Working Party
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
Clinical Trials & Observations
Nicoletta Testoni,Giulia Marzocchi,Simona Luatti,Marilina Amabile,Carmen Baldazzi,Monica Stacchini,Mauro Nanni,Giovanna Rege-Cambrin,Emilia Giugliano,Ursula Giussani,Elisabetta Abruzzese,Simonetta Kerim,Maria Grazia Grimoldi,Alessandro Gozzetti,Barbara Crescenzi,Carlo Carcassi,Paolo Bernasconi,Antonio Cuneo,Francesco Albano,Giuseppina Fugazza,Alfonso Zaccaria,Giovanni Martinelli,Fabrizio Pane,Gianantonio Rosti,Michele Baccarani
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Clinical Trials & Observations
Martin C. Müller,Jorge E. Cortes,Dong-Wook Kim,Brian J. Druker,Philipp Erben,Ricardo Pasquini,Susan Branford,Timothy P. Hughes,Jerald P. Radich,Lynn Ploughman,Jaydip Mukhopadhyay,Andreas Hochhaus
Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition
Brief Report
Carlos Fernández de Larrea,María Teresa Cibeira,Montserrat Elena,Juan Ignacio Arostegui,Laura Rosiñol,Montserrat Rovira,Xavier Filella,Jordi Yagüe,Joan Bladé
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
Yongchao Wang,Warren Fiskus,Daniel G. Chong,Kathleen M. Buckley,Kavita Natarajan,Rekha Rao,Atul Joshi,Ramesh Balusu,Sanjay Koul,Jianguang Chen,Andrew Savoie,Celalettin Ustun,Anand P. Jillella,Peter Atadja,Ross L. Levine,Kapil N. Bhalla
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activation
Goichi Yoshimoto,Toshihiro Miyamoto,Siamak Jabbarzadeh-Tabrizi,Tadafumi Iino,Jennifer L. Rocnik,Yoshikane Kikushige,Yasuo Mori,Takahiro Shima,Hiromi Iwasaki,Katsuto Takenaka,Koji Nagafuji,Shin-ichi Mizuno,Hiroaki Niiro,Gary D. Gilliland,Koichi Akashi
PLATELETS AND THROMBOPOIESIS
Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34+ cells are functionally active in an ex vivo flow model of thrombosis
Isabelle I. Salles,Tim Thijs,Christine Brunaud,Simon F. De Meyer,Johan Thys,Karen Vanhoorelbeke,Hans Deckmyn
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor
Phillip Scheinberg,Jan J. Melenhorst,Jason M. Brenchley,Brenna J. Hill,Nancy F. Hensel,Pratip K. Chattopadhyay,Mario Roederer,Louis J. Picker,David A. Price,A. John Barrett,Daniel C. Douek
VASCULAR BIOLOGY
-
Cover Image
Cover Image
B cells are central players of humoral immune responses. After binding to their antigens, humoral antibodies can lead to complement activation, antibody-mediated cellular cytotoxicity, and Fc-mediated endocytosis. Besides producing antibodies, B cells exert several other important antibody-independent functions such as antigen presentation, cytokine production, and immunoregulation. Professional illustration by A. Y. Chen. See the article by Shimabukuro-Vornhagen et al on page 4919.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals